Double Epigenetic Modulation of High-Dose Chemotherapy With Azacitidine and Vorinostat for Patients With Refractory or Poor-Risk Relapsed Lymphoma

BACKGROUND: More active high-dose chemotherapy (HDC) regimens are needed for refractory lymphomas. The authors previously combined infusional gemcitabine with busulfan and melphalan (Gem/Bu/Mel) pursuing DNA damage repair inhibition. Subsequently, they combined Gem/Bu/Mel with vorinostat, which faci...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Principais autores: Nieto, Yago, Valdez, Benigno C., Thall, Peter F., Jones, Roy B., Wei, Wei, Myers, Alan, Hosing, Chitra, Ahmed, Sairah, Popat, Uday, Shpall, Elizabeth J., Qazilbash, Muzaffar, Gulbis, Alison, Anderlini, Paolo, Shah, Nina, Bashir, Qaiser, Alousi, Amin, Oki, Yasuhiro, Fanale, Michelle, Dabaja, Bouthaina, Pinnix, Chelsea, Champlin, Richard, Andersson, Borje S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4992444/
https://ncbi.nlm.nih.gov/pubmed/27203405
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30100
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados